ExpreS2ion co-author of article demonstrating that human antibodies from RH5 vaccine block binding to blood cells

Report this content

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that a scientific article, documenting that human antibodies against the RH5 protein can stop the malaria parasite from entering human blood cells, has been published in the highly renowned journal Cell. The article is based on a clinical study conducted by researchers at the University of Oxford together with a consortium of research entities including ExpreS2ion.

The clinical study was a part of a clinical trial in Oxford of the first vaccine that targets the RH5 malaria protein in a phase I/IIa study. The study was led by researchers from the University of Oxford, and it was conducted in collaboration with researchers at the Burnet Institute (Australia), Center for Global Infectious Disease Research at the Seattle Children’s Research Institute (USA), Laboratory of Malaria and Vector Research (USA), Cell Surface Signalling Laboratory at the Wellcome Trust Sanger Institute (Cambridge) and ExpreS2ion Biotechnologies (Denmark).

The findings presented in the article, that include identification of protective antibodies which may be key to an effective malaria vaccine, show great promise for the project.

“It is very pleasant to see that these clinical results sustain RH5 as a target and the continued development of the RH5 vaccine, that was initially enabled and then produced using our ExpreS2 platform,” says ExpreS2ion’s CEO Dr. Steen Klysner.

The article was co-authored by ExpreS2ion’s CSO Dr. Wian de Jongh and can be reached via this link: https://www.cell.com/cell/fulltext/S0092-8674(19)30553-7 

More information can be found in this press release published by the University of Oxford: http://www.ox.ac.uk/news/2019-06-13-identification-protective-antibodies-may-be-key-malaria-vaccine

Malaria facts (WHO)

Malaria is a life-threatening disease caused by parasites transmitted into the human body via infected female Anopheles mosquitoes. Even though the disease is preventable and curable, it is estimated that 219 million people in 87 countries were infected with malaria in 2017, and the number of deaths were estimated to 435,000 in the same year. In a market assessment study conducted by the Boston Consulting Group sponsored by the Malaria Vaccine Initiative, the global market value for malaria vaccines was estimated to up to USD 400 million per year based on estimated malaria vaccine demand.

Certified Adviser 

Sedermera Fondkommission

E-post: CA@sedermera.se

Telephone: +46 40-615 14 10

For further information about ExpreS2ion Biotech Holding AB, please contact:

Dr. Steen Klysner, CEO
Telephone: +45 2062 9908
E-mail: sk@expres2ionbio.com

About ExpreS2ion

ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. The subsidiary has developed a unique proprietary platform technology, ExpreS2, that can be used for fast and efficient preclinical and clinical development as well as robust production of complex proteins for new vaccines and diagnostics. Since the Company was founded in 2010, it has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with leading research institutions and companies, demonstrating superior efficiency and success rates. In addition, ExpreS2ion develops novel VLP based vaccines through the joint venture AdaptVac ApS which was founded in 2017.



Documents & Links